Resolution of COVID-19 induced anosmia following treatment with ST266.

ABSTRACT:

Background

Persistent anosmia following COVID-19 disease affects a significant subset of patients. Symptoms of this olfactory dysfunction negatively impact patient quality of life, and effective treatments are lacking; therefore, novel therapies that restore the ability to smell have tremendous clinical potential.

Case report

A 46-year-old female enrolled in a phase I clinical trial to assess the safety of targeted intranasal administration of a novel acellular secretome therapy (ST266) in patients diagnosed as glaucoma suspects. The patient reported greater than one year history of loss of smell that started following a presumed positive case of COVID-19. Following a 28-day treatment course of bilateral intranasal administration of ST266, the patient had resolution of her l

SUBMITTER: Bhutani DL 

PROVIDER: S-EPMC9444303 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature